Evidence map›Paper›PMID 40923698›Full record

ArticleThe Kaohsiung journal of medical sciences2026

Rosuvastatin Upregulates RCOR1 to Repress C10ORF10 Transcription and Alleviate Oxidative Stress and Plaque Formation in Atherosclerosis.

Xin Fu, Chuang Liu, Ya-Li Chen, Jie-Lin Qin, Ting-Ting Wang, Shan-Shan Fu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Kaohsiung journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xin FuDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.ORCID https://orcid.org/0009-0007-9751-3062
Chuang LiuDepartment of Comprehensiveness, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
Ya-Li ChenDepartment of Comprehensiveness, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
Jie-Lin QinDepartment of Comprehensiveness, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
Ting-Ting WangDepartment of Comprehensiveness, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
Shan-Shan FuDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rosuvastatin (RVS) is an HMG-CoA reductase inhibitor with lipid-lowering properties. This study aims to investigate the role of RVS in plaque formation in atherosclerosis (AS) and its functional mechanism. ApoE

Indexed as

AtherosclerosisNuclear Receptor Co-Repressor 1Oxidative StressPlaque, AtheroscleroticRosuvastatin CalciumAnimalsAortaApolipoproteins ECell ProliferationDiet, High-FatDisease Models, AnimalHumansMaleMiceMice, Inbred C57BLMuscle, Smooth, VascularApolipoproteins ENuclear Receptor Co-Repressor 1Reactive Oxygen SpeciesRosuvastatin CalciumatherosclerosisC10ORF10HVSMCsRCOR1rosuvastatin

Identifiers

PMID40923698
PMCPMC12955935

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.